Chemed Corp. (NYSE:CHE) EVP Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $228.45, for a total transaction of $228,450.00. Following the sale, the executive vice president now directly owns 36,809 shares in the company, valued at approximately $8,409,016.05. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Chemed Corp. (NYSE CHE) opened at $235.01 on Friday. The firm has a market cap of $3,752.17, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 4.97 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings data on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to the consensus estimate of $414.34 million. Chemed Corp. had a net margin of 4.62% and a return on equity of 27.69%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.73 EPS. analysts predict that Chemed Corp. will post 4.73 EPS for the current year.
The firm also recently disclosed a dividend, which will be paid on Monday, December 4th. Stockholders of record on Monday, November 13th will be issued a $0.28 dividend. The ex-dividend date is Friday, November 10th. Chemed Corp.’s dividend payout ratio (DPR) is currently 24.89%.
TRADEMARK VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/05/spencer-s-lee-sells-1000-shares-of-chemed-corp-che-stock.html.
Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of Chemed Corp. by 37.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,663 shares of the company’s stock valued at $1,750,000 after acquiring an additional 2,377 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Chemed Corp. by 5.7% in the 3rd quarter. Prudential Financial Inc. now owns 58,576 shares of the company’s stock valued at $11,835,000 after purchasing an additional 3,183 shares during the period. Cape Cod Five Cents Savings Bank lifted its stake in shares of Chemed Corp. by 8.3% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 5,966 shares of the company’s stock valued at $1,206,000 after purchasing an additional 455 shares during the period. Stevens Capital Management LP lifted its stake in shares of Chemed Corp. by 45.7% in the 3rd quarter. Stevens Capital Management LP now owns 10,454 shares of the company’s stock valued at $2,112,000 after purchasing an additional 3,280 shares during the period. Finally, Chicago Equity Partners LLC lifted its stake in shares of Chemed Corp. by 80.2% in the 3rd quarter. Chicago Equity Partners LLC now owns 31,595 shares of the company’s stock valued at $6,384,000 after purchasing an additional 14,065 shares during the period. 97.24% of the stock is currently owned by institutional investors and hedge funds.
CHE has been the topic of several research analyst reports. TheStreet downgraded shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research report on Tuesday, July 25th. Royal Bank Of Canada boosted their target price on shares of Chemed Corp. to $232.00 and gave the stock a “sector perform” rating in a research report on Tuesday, October 31st. KeyCorp reaffirmed a “hold” rating on shares of Chemed Corp. in a report on Friday, October 27th. Zacks Investment Research downgraded shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, BidaskClub downgraded shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $236.00.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.